
Join the Illexcor revolution
At Illexcor Therapeutics, we're on a mission to discover and develop revolutionary oral HbS polymerization inhibitors for sickle cell disease. Our goal is to deliver a life-changing treatment to provide hope to this underserved global patient community. Our focus is on rare hematological diseases, with established expertise in developing novel therapies for adults and children with sickle cell disease, and this drives everything we do. As an early-phase clinical stage company, we offer experienced professionals something that's increasingly rare in today's biopharma landscape: the opportunity to drive meaningful scientific advancement with the agility and purpose of a focused team.